Drugs / narmafotinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07026279 | Aug 2025 → Jul 2029 expected | malignant pancreatic neoplasm | Amplia Therapeutics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05355298 | May 2022 → Feb 2027 expected | pancreatic ductal adenocarcinoma | Amplia Therapeutics Limited | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | narmafotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07026279 ↗ |
| Known as | AMP945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05355298 ↗ |
| Action | Inhibit | “focal adhesion kinase (FAK) inhibitor AMP945” NCT05355298 ↗ |
| Modality | Small molecule | — CHEMBL3689071 ↗ |
| Route | Oral | “Participants will take narmafotinib as oral capsules every day.” NCT07026279 ↗ |